Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

Pembrolizumab Shows Activity in Advanced Cervical Cancer

  • Dave Levitan
November 8, 2017
  • Oncology Nursing Gynecologic Cancers, Cervical Cancer, Gynecologic Cancers

The immune checkpoint inhibitor pembrolizumab demonstrated antitumor activity in a small trial of patients with advanced cervical cancer. The agent had a similar toxicity profile to that seen in other malignancies.

Though patients who present with localized cervical cancer have a good prognosis, this is not the case in those who present with advanced disease. “The prognosis for patients with advanced disease is poor, with a 5-year survival rate of only 17%,” wrote study authors led by Jean-Sébastien Frenel, MD, of the Institut de Cancérologie de l’Ouest in Saint-Herblain, France. Limited treatment options are currently available for these patients, but it was recently determined that PD-L1 is expressed in cervical cancer, suggesting that pembrolizumab may be effective.

The KEYNOTE-028 trial included 20 cohorts of different malignancies; the cervical cancer cohort included 24 patients with a median age of 42 years. Most of these patients (92%) had received prior radiation therapy, and 63% had received at least two prior lines of therapy for advanced disease. The results of the analysis were published online ahead of print in the Journal of Clinical Oncology.

After a median follow-up of 11 months, the overall response rate was 17%; all four responders had a partial response, and another three patients had stable disease (13%). Sixteen patients had progressive disease (67%).

The median time to response among those who did achieve a partial response was 1.9 months, and the median duration of response was 5.4 months; two of the four responders maintained a response for over 6 months. All four responders demonstrated PD-L1 expression in the tumor only.

The median progression-free survival in all patients was 2 months, and the progression-free survival rate at 6 and 12 months was 21% and 4%, respectively. The median overall survival was 11 months, and the 6- and 12-month overall survival rates were 67% and 40%, respectively.

A total of 18 patients had adverse events considered related to the study drug; the most common were rash (21%) and pyrexia (17%). Five patients had grade 3 treatment-related adverse events, and these included neutropenia, rash, colitis, Guillain-Barre syndrome, and proteinuria. Four patients (17%) experienced a serious adverse event that was considered treatment-related.

“Results from this analysis of the phase Ib KEYNOTE-028 trial suggest that pembrolizumab is well tolerated and has durable antitumor activity in patients with PD-L1-positive advanced cervical cancer,” the authors concluded. The KEYNOTE-0158 phase II trial is now underway in this setting, and the value of PD-L1 immunohistochemistry as a biomarker is also being assessed.

Related Articles

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".